India : Bharat Biotech’s Covaxin shows 77.8% efficacy in phase 3 trials

India : Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trials

India : Bharat Biotech’s Covaxin shows 77.8% efficacy in phase 3 trials

Hyderabad-based biotechnology company Bharat Biotech, that manufactures Covaxin, has submitted phase-III clinical trial data of its vaccine to the Drugs Controller General of India. The results of Phase 3 clinical trials of Covaxin vaccine have come. Data from the trials of Covaxin show the vaccine against Covid-19 is 77.8% effective.

The World Health Organisation (WHO) has also accepted Bharat Biotech’s Expression of Interest (EoI) for Covaxin and has scheduled a pre-submission meeting tomorrow (June 23). Bharat Biotech expects this to take Covaxin a step closer to getting a WHO emergency use listing. Though the meeting will not be a detailed review of the Covaxin vaccine, Bharat Biotech will have an opportunity to submit a summary on the overall quality of the jab, according to the WHO.

Covaxin, the country’s indigenously-developed COVID-19 vaccine, is among the three vaccines that are being used in the country to inoculate people against the viral infection. Bharat Biotech had conveyed to the Centre that it has already submitted 90 percent of documents to WHO for obtaining EUL for Covaxin. It had further said that the remaining documents would be submitted this month.